Sevabertinib: FDA Approval Ushers in a New Era for Lung Cancer and Precision Medicine The FDA’s recent approval of sevabertinib signals a profound shift in precision medicine, especially for lung cancer patients with limited options. For the first time, a cancer drug originating from t... academic-industry collaboration Broad Institute cancer drug drug discovery FDA approval HER2 mutation lung cancer precision medicine